Bright Health Group, Inc. ("Bright Health") (NYSE: BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today announced Mike Mikan, CEO and President, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, in San Francisco, CA.
Bright Health’s presentation will begin at 6:00 p.m. ET / 3:00 p.m. PT. A live webcast of the presentation will be available at https://investors.brighthealthgroup.com/events-and-presentations/events/default.aspx.
A webcast replay of the presentation will be available afterwards via Bright Health’s Investor Relations page at investors.brighthealthgroup.com.
About Bright Health Group
Bright Health Group is a technology enabled, value-based healthcare company that organizes and operates networks of affiliate care providers to be successful at managing population risk. We focus on serving aging and underserved consumers that have unmet clinical needs through our Fully Aligned Care Model in Florida, Texas and California, some of the largest markets in healthcare where 26% of the U.S. aging population call home. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together. For more information, visit www.brighthealthgroup.com.
Last Trade: | US$4.98 |
Daily Change: | -0.09 -1.68 |
Daily Volume: | 2,829 |
Market Cap: | US$41.230M |
November 07, 2024 October 30, 2024 August 07, 2024 May 08, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB